丙肝治愈与随访：口服抗病毒方案、治愈标准与肝癌监测

先看懂四件事：谁需要治疗、方案怎么选、什么叫治愈、治愈后做什么Hepatitis C: Cure & Follow-up

丙肝的诊疗链条清晰而短：抗体初筛 → HCV RNA 确认现症感染 → 基因型与肝纤维化评估 → 口服直接抗病毒药物 8–12 周 → 治疗结束后 12 周复查 HCV RNA 确认治愈 → 已肝硬化者继续肝癌监测、所有治愈者预防再感染。

发病机理：从炎症到肝硬化与肝癌：丙肝为什么必须治Pathogenesis

丙肝病毒不是直接杀死肝细胞，而是通过持续的免疫反应造成炎症与纤维化。这个过程常常没有症状，等到出现腹水或出血时往往已经肝硬化——所以「没有不舒服」从来不是不治疗的理由。

哪些因素增加肝硬化、肝癌与再感染风险

两个容易被忽略的问题

怎么检查：病毒、肝功与影像Assessment

怎么治疗：口服方案、疗程与特殊人群Treatment

治疗方案与预期疗效一览

日常管理：复发、再感染与肝癌筛查Daily Management

十个常见误区Ten Common Misconceptions

参考文献与证据来源References & Evidence

本页共 24 条文献，来自国际共识与指南、随机对照试验、荟萃分析与机制研究，链接指向 PubMed。每条结论后的编号对应下方文献；证据不足或结论不一致之处已在正文标注。

1. 全球负担建模研究（2015 年丙肝病毒感染患病率与基因型分布）Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176. pubmed.ncbi.nlm.nih.gov/28404132
2. 分子流行病学研究（中国大陆流行的丙肝病毒基因型与亚型）Chen Y, Yu C, Yin X, Guo X, Wu S, Hou J. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect. 2017;6(11):e95. pubmed.ncbi.nlm.nih.gov/29089588
3. 横断面研究（中国慢性丙肝患者的病毒与宿主基因型分布及临床相关性）Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2014;29(3):545-553. pubmed.ncbi.nlm.nih.gov/24090188
4. 基于人群的观察性研究（2004 至 2014 年中国乙肝与丙肝的流行病学）Liu Z, Yang Q, Shi O, Ye W, Chen X, Zhang T. The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: An observational population-based study. J Viral Hepat. 2018;25(12):1543-1554. pubmed.ncbi.nlm.nih.gov/29851287
5. 三期随机试验（初治基因 Ⅰ型丙肝的 ledipasvir 联合 sofosbuvir 方案：ION-1）Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898. pubmed.ncbi.nlm.nih.gov/24725239
6. 三期随机试验（经治基因 Ⅰ型丙肝的 ledipasvir 联合 sofosbuvir 方案：ION-2）Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493. pubmed.ncbi.nlm.nih.gov/24725238
7. 三期随机试验（无肝硬化患者 8 周与 12 周方案比较：ION-3）Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW, ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-1888. pubmed.ncbi.nlm.nih.gov/24720702
8. 三期随机试验（sofosbuvir 联合 velpatasvir 治疗基因 Ⅰ、Ⅱ、Ⅳ、Ⅴ、Ⅵ型：ASTRAL-1）Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S, ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599-2607. pubmed.ncbi.nlm.nih.gov/26571066
9. 三期随机试验（sofosbuvir 联合 velpatasvir 治疗基因 Ⅱ、Ⅲ型：ASTRAL-2 与 ASTRAL-3）Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M, ASTRAL-2 Investigators, ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015;373(27):2608-2617. pubmed.ncbi.nlm.nih.gov/26575258
10. 三期随机试验（失代偿肝硬化患者的 sofosbuvir 联合 velpatasvir 治疗：ASTRAL-4）Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS, Charlton M, ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015;373(27):2618-2628. pubmed.ncbi.nlm.nih.gov/26569658
11. 三期随机试验（glecaprevir 联合 pibrentasvir 8 周与 12 周方案：ENDURANCE-1 与 ENDURANCE-3）Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354-369. pubmed.ncbi.nlm.nih.gov/29365309
12. 单臂开放标签三期试验（亚洲人群 sofosbuvir 联合 velpatasvir 治疗慢性丙肝）Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, Le Manh H, Gao Y, Mou Z, Sobhonslidsuk A, Dou X, Thongsawat S, Nan Y, Tan CK, Ning Q, Tee HP, Mao Y, Stamm LM, Lu S, Dvory-Sobol H, Mo H, Brainard DM, Yang YF, Dao L, Wang GQ, Tanwandee T, Hu P, Tangkijvanich P, Zhang L, Gao ZL, Lin F, Le TTP, Shang J, Gong G, Li J, Su M, Duan Z, Mohamed R, Hou JL, Jia J. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019;4(2):127-134. pubmed.ncbi.nlm.nih.gov/30555048
13. 三期随机试验（grazoprevir 联合 elbasvir 治疗慢性肾病 4 至 5 期患者：C-SURFER）Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H, Martin P, Pol S, Londoño MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537-1545. pubmed.ncbi.nlm.nih.gov/26456905
14. 单臂开放标签三期试验（glecaprevir 联合 pibrentasvir 治疗严重肾功能不全患者：EXPEDITION-4）Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida EM, Nelson DR, Collins C, Lei Y, Kosloski M, Mensa FJ. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017;377(15):1448-1455. pubmed.ncbi.nlm.nih.gov/29020583
15. 三期随机试验（经治患者的 sofosbuvir、velpatasvir 与 voxilaprevir 方案：POLARIS-1 与 POLARIS-4）Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S, POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017;376(22):2134-2146. pubmed.ncbi.nlm.nih.gov/28564569
16. 叙述性综述（无干扰素方案中的丙肝病毒耐药）Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology. 2016;151(1):70-86. pubmed.ncbi.nlm.nih.gov/27080301
17. 回顾性队列研究（直接抗病毒治疗与新发肝癌风险）Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018;47(9):1278-1287. pubmed.ncbi.nlm.nih.gov/29516535
18. 回顾性队列研究（退伍军人丙肝患者获得持续病毒学应答后的肝癌风险）El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016;64(1):130-137. pubmed.ncbi.nlm.nih.gov/26946190
19. 前瞻队列研究（埃及丙肝队列中直接抗病毒治疗后肝癌复发率升高）El Kassas M, Funk AL, Salaheldin M, Shimakawa Y, Eltabbakh M, Jean K, El Tahan A, Sweedy AT, Afify S, Youssef NF, Esmat G, Fontanet A. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis. J Viral Hepat. 2018;25(6):623-630. pubmed.ncbi.nlm.nih.gov/29274197
20. 队列研究（直接抗病毒治疗降低肝硬化患者的肝癌复发率）Virlogeux V, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, Ouziel G, Poinsot D, Lebossé F, Ecochard M, Radenne S, Benmakhlouf S, Koffi J, Lack P, Scholtes C, Uhres AC, Ducerf C, Mabrut JY, Rode A, Levrero M, Combet C, Merle P, Zoulim F. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver Int. 2017;37(8):1122-1127. pubmed.ncbi.nlm.nih.gov/28423231
21. 系统评价与荟萃分析（合并肝癌的慢性丙肝患者抗病毒治疗的持续病毒学应答）Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019;71(3):473-485. pubmed.ncbi.nlm.nih.gov/31096005
22. 系统评价与荟萃分析（注射吸毒人群成功治疗后的丙肝再感染）Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. J Hepatol. 2020;72(4):643-657. pubmed.ncbi.nlm.nih.gov/31785345
23. 队列研究（直接抗病毒药物治疗丙肝相关混合型冷球蛋白血症）Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, Steele D, Thiim M, Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63(2):408-417. pubmed.ncbi.nlm.nih.gov/26474537
24. 建模研究（为实现 WHO 2030 消除目标所需的干预水平）European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325-336. pubmed.ncbi.nlm.nih.gov/28397696